Research programme: cancer therapeutics - MaxCyte

Drug Profile

Research programme: cancer therapeutics - MaxCyte

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MaxCyte; Washington University
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Haematological malignancies

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical study presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 21 Dec 2016 Early research in Haematological malignancies in USA (unspecified route)
  • 21 Dec 2016 MaxCyte and Washington University agree to co-develop new generation of Chimeric Antigen Receptor T cell therapy for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top